---
visibility: public
title: LSD and Psilocybin Comparison
description: Scientific comparison of therapeutic potential, risks, and regulatory status of classic psychedelics
category: research
tags: [psychedelics, lsd, psilocybin, mental-health, therapy, neuroscience]
updated: 2026-01-09
status: complete
---

# LSD and psilocybin: A comprehensive scientific comparison of therapeutic potential and risks

Both LSD and psilocybin have emerged as legitimate psychiatric treatments with the first Phase 3 trial success reported in June 2025, marking a historic milestone in psychedelic medicine. These classic serotonergic psychedelics share a primary mechanism—agonism at the serotonin 5-HT2A receptor— yet differ meaningfully in duration, receptor profiles, and therapeutic accessibility. Current evidence demonstrates robust efficacy for treatment-resistant depression, anxiety disorders, addiction, and end-of-life distress, with **effect sizes substantially exceeding conventional treatments**. While both substances show remarkably favorable safety profiles in controlled settings, they carry genuine risks for individuals with personal or family histories of psychotic disorders. The regulatory landscape is evolving rapidly: psilocybin leads with three FDA Breakthrough Therapy designations and active state-level programs in Oregon and Colorado, while LSD received its first Breakthrough designation for generalized anxiety disorder in March 2024. 

——

## How psychedelics rewire the brain: neuroplasticity mechanisms

Both compounds promote profound structural and functional changes in neural architecture, operating through overlapping but distinct pathways. The primary mechanism involves 5-HT2A receptor activation in the neocortex, initiating intracellular signaling cascades that drive synaptogenesis and dendritogenesis. 

A landmark 2023 study in *Nature Neuroscience* (Moliner et al.) revealed that psychedelics bind directly to **TrkB, the brain-derived neurotrophic factor (BDNF) receptor, with 1,000-fold higher affinity than traditional antidepressants**.  LSD binds TrkB at approximately 0.9 nM, while psilocin (the active metabolite of psilocybin) binds at 6.73 nM.  Critically, this research demonstrated that plasticity-promoting effects are independent of the hallucinogenic 5-HT2A pathway, suggesting the antidepressant and neuroplastic benefits may eventually be separable from the psychedelic experience itself.  

Research from UC Davis (Ly et al., 2018, *Cell Reports*) established that LSD nearly doubles dendritic spine density on cortical neurons, proving more potent than ketamine in promoting neurite growth. Yale University studies (Shao et al., 2021, *Neuron*) demonstrated that a single psilocybin dose induces rapid growth of dendritic spines in mouse frontal cortex within **24 hours, with increases persisting for at least one month**. Human studies confirm that LSD dose-dependently elevates plasma BDNF levels, with significant increases observed at 200 μg doses six hours after administration. 

Both substances activate the mTOR (mammalian target of rapamycin) pathway essential for synaptic protein synthesis   and upregulate immediate early genes including Arc, c-Fos, and Egr2 within 1-1.5 hours. The “plasticity window” initiated by 5-HT2A activation appears to last days to weeks, potentially explaining the sustained therapeutic benefits observed from single doses.

——

## Neurogenesis: creating new brain cells

Psilocybin demonstrates dose-dependent effects on hippocampal neurogenesis—the creation of new neurons in the brain’s memory center. Preclinical research from Catlow et al. (2013, *Experimental Brain Research*) found that low doses (0.1-0.5 mg/kg) promoted neurogenesis in mouse hippocampus, while higher doses actually decreased newborn neuron counts. This finding parallels clinical approaches emphasizing controlled dosing.

More recent studies (Rosas-Sánchez et al., 2024; Du et al., 2023) show psilocybin reverses stress-induced reductions in DCX-positive (immature neurons) and BrdU-positive (proliferating) cells in the dentate gyrus. The related tryptamine 5-MeO-DMT stimulates neurogenesis and spinogenesis in mice 12 hours post-treatment, increasing proliferation of neuronal progenitor cells and survival of newborn granule cells.

LSD’s neurogenesis data remains more limited. An immunohistochemistry study found no effect on proliferating cells in adult rat hippocampus with either acute or chronic administration. However, 90-day LSD administration significantly modulated expression of genes involved in synaptic plasticity (Nr2a, Krox20), neurotransmission (Drd2, Gabrb1), and neuropeptide signaling including BDNF, suggesting indirect support for neuronal survival and function.

——

## Memory effects show a complex acute-to-subacute pattern

Classic psychedelics produce a distinctive temporal pattern: **acute impairment during intoxication followed by subacute enhancement** in specific memory domains. During the experience, both substances dose-dependently impair spatial working memory, verbal working memory, and semantic memory while leaving decision-making relatively intact. Research from University of Zurich (Preller et al., 2019, *Psychological Medicine*) confirmed LSD (100 μg) significantly impairs executive functions and cognitive flexibility, with deficits normalized by ketanserin pretreatment—confirming 5-HT2A mediation.

The “afterglow” period tells a different story. Beckley Foundation research (Wießner et al., 2022, *European Neuropsychopharmacology*) found that 24 hours after 50 μg LSD administration, participants showed improved visuospatial memory and enhanced phonological verbal fluency, though cognitive flexibility remained impaired. This pattern represents both therapeutic benefit and temporary limitation.

The therapeutic implications center on memory reconsolidation. Psychedelics appear to enhance subjective vividness of autobiographical memories while potentially facilitating reprocessing of traumatic material. Psilocybin prevents reinstatement of alcohol-seeking behavior by disrupting reconsolidation of alcohol-related memories (Benvenuti et al., 2023). Low-dose psilocybin facilitates extinction of conditioned fear responses in mice,  supporting potential PTSD applications.  A Johns Hopkins clinical trial is currently assessing psilocybin for depression in patients with mild cognitive impairment or early Alzheimer’s disease, exploring whether enhanced neuroplasticity might counteract synaptic atrophy. 

——

## Depression treatment shows landmark Phase 3 success

The first Phase 3 clinical trial results for a classic psychedelic were reported in June 2025, marking a watershed moment for psychiatric medicine. COMPASS Pathways’ COMP005 trial demonstrated that a single 25 mg psilocybin dose produced a **statistically significant (p<0.001) and clinically meaningful 3.6-point reduction in MADRS depression scores** compared to placebo at week six in 258 patients with treatment-resistant depression across 32 US sites.  

Earlier Phase 2 data established the foundation. Johns Hopkins research (Davis et al., 2021, *JAMA Psychiatry*) showed **effect sizes of Cohen’s d = 2.5-2.6**—considered extraordinarily large—with 71% response rates and 54-58% remission rates.  Benefits appeared within one day and persisted at 12-month follow-up. Imperial College London’s head-to-head comparison with escitalopram (Carhart-Harris et al., 2021, *NEJM*) found psilocybin produced 70% response rates versus 48% for the SSRI, and 57% remission versus 28%, though the primary endpoint difference did not reach statistical significance.  

A critical advantage emerges in treatment duration: psilocybin produces sustained effects from one to two administrations versus daily indefinite dosing with SSRIs. The average efficacy duration from a single 25 mg dose is approximately 12 weeks, with a subgroup showing substantially longer benefit.  This represents a fundamentally different treatment paradigm—episodic rather than continuous pharmacotherapy.

Psilocybin received FDA Breakthrough Therapy designation for treatment-resistant depression in 2018 (COMPASS Pathways) and for major depressive disorder in 2019 (Usona Institute). Usona’s Phase 3 uAspire trial launched in March 2024 with 240 participants.

——

## Anxiety disorders respond to both substances

LSD has emerged as particularly promising for generalized anxiety disorder. MindMed’s Phase 2b trial of MM-120 (lysergide d-tartrate) showed **65% clinical response and 48% remission rates at 12 weeks** from a single 100 μg dose—notably without accompanying psychotherapy.   The FDA granted Breakthrough Therapy designation in March 2024,  and Phase 3 trials with 440 participants are now underway, representing the first LSD Phase 3 program in history.

University Hospital Basel research (Holze et al., 2023, *Biological Psychiatry*) demonstrated that 200 μg LSD produced sustained anxiety reductions of d = -1.18 at 16 weeks, with benefits persisting at 12-month follow-up. A Phase 2 trial with 42 patients with anxiety (with or without life-threatening illness) showed significant reductions in both anxiety and depression measures.

Psilocybin’s anxiety evidence comes primarily from cancer-related distress. Johns Hopkins (Griffiths et al., 2016) and NYU (Ross et al., 2016) landmark studies in cancer patients  showed **78-83% clinical response rates sustained at 6 months** for anxiety and depression. Follow-up data from NYU demonstrates effects persisting 4.5 years post-treatment without additional psychedelic sessions. 

——

## PTSD research enters clinical development

COMPASS Pathways completed the first Phase 2 psilocybin trial specifically for clinically-confirmed PTSD in early 2025 (McGowan et al., *Journal of Psychopharmacology*). In 22 participants, a single 25 mg dose produced clinically meaningful reductions across all four PTSD symptom clusters, with rapid improvement appearing the day after treatment. Safety was acceptable—91.4% of treatment-emergent adverse events resolved by the next day.

The proposed mechanisms for trauma processing include memory reconsolidation facilitation (allowing reprocessing without retraumatization), reduced amygdala hyperreactivity modulating fear responses, and enhanced neuroplasticity promoting new neural pathway formation. Unlike MDMA, which received a setback when the FDA declined Lykos Therapeutics’ application in August 2024, psilocybin research for PTSD continues advancing. 

——

## Addiction treatment demonstrates compelling efficacy

### Alcohol use disorder

The largest randomized controlled trial (Bogenschutz et al., 2022, *JAMA Psychiatry*) compared psilocybin-assisted therapy to active placebo in 93 participants. Heavy drinking days dropped to **9.7% (psilocybin) versus 23.6% (placebo)** during the 32-week follow-up, representing an effect size of Hedges g = 0.52. At week 36, abstinence rates reached 47.9% versus 24.4%. Historical meta-analysis of 1960s LSD research (Krebs & Johansen, 2012) showed comparable benefits: OR = 1.96 favoring LSD, with single-dose efficacy matching daily naltrexone or acamprosate.

### Tobacco cessation

Johns Hopkins pilot research (Johnson et al., 2014, 2017) produced remarkable results: **80% abstinence at 6 months and 60% at 30 months**—compared to ~35% for varenicline, the most effective approved treatment. An NIH-funded multisite Phase 2/3 trial is now underway, representing the first federal psychedelic treatment grant in over 50 years.

The mechanisms underlying anti-addiction effects include disruption of default mode network patterns associated with rigid thinking, mystical experiences that correlate strongly with outcomes, enhanced introspection enabling perspective shifts, and neuroplasticity that may “reopen critical period-like” states enabling behavioral modification.

——

## Other psychiatric applications show varying evidence strength

### OCD

Early University of Arizona research (Moreno et al., 2006) showed all 9 participants experienced symptom reduction (23-100% decrease in Y-BOCS). Recent Imperial College/Cambridge research (2025) demonstrated **Cohen’s d = 0.82** for compulsion reduction at one week with 10 mg psilocybin, though effects diminished over subsequent weeks. Yale trials are ongoing.

### End-of-life anxiety

The strongest evidence base exists here. Johns Hopkins and NYU studies showed **80% of cancer patients achieved clinically significant decreases in depression and anxiety at 6 months**, with ~60% achieving remission. Remarkably, 67% rated the experience among the top five most meaningful of their lives. Swiss research with LSD (Gasser et al., 2014) showed 77% experienced lasting anxiety relief at one year.

### Eating disorders

Phase 1 research (Peck et al., 2023, *Nature Medicine*) established safety in 10 women with anorexia nervosa. Preliminary efficacy showed 40% achieved normal eating disorder examination scores at 3-month follow-up. Phase 2 trials are underway at UC San Diego and King’s College London. No FDA-approved medications currently exist for anorexia, making this application particularly significant.

——

## Lifestyle and psychological benefits extend beyond clinical populations

Research in healthy volunteers reveals lasting positive changes from psychedelic experiences. Johns Hopkins studies (MacLean et al., 2011) demonstrated **significant increases in the personality trait Openness persisting more than one year** after high-dose psilocybin—notable because personality traits are typically stable after age 30.  A 2024 Swedish population study found psychedelic users showed markedly higher Openness (effect size d = 1.72) and lower depression scores. 

The mystical experience dimension proves particularly important. In the landmark 2006 Johns Hopkins study, **58% rated the psilocybin experience among the top five most personally meaningful of their lives**, and 67% among the most spiritually significant.  These ratings correlated with sustained improvements in well-being and predicted therapeutic outcomes in clinical populations. 

Creativity research shows nuanced effects. During acute intoxication, macrodoses tend to impair task-based creativity, while microdoses show enhancement trends. However, 7 days post-psilocybin, the number of novel ideas increases significantly (Mason et al., 2021, *Translational Psychiatry*). Emotional empathy enhances for at least two weeks following psilocybin, while cognitive empathy remains unchanged.

——

## Risks require careful consideration despite favorable safety profile

### Psychological risks

Challenging experiences are common: **39% of volunteers experienced extreme anxiety or fear** at high doses (20-30 mg/70kg psilocybin).  In clinical trials, majority experienced challenging states including sadness, grief, and despair, with 31% fearing the state would last forever.  These experiences are manageable with proper support and rarely lead to lasting harm in controlled settings.

The psychosis risk demands particular attention. A 2025 meta-analysis in *Molecular Psychiatry* found **no long-lasting psychotic reactions in healthy individuals without personal or familial risk factors** under controlled experimental conditions. However, for those who do experience psychedelic-induced psychosis, considerably increased risk of transition to schizophrenia emerged.  This explains why all clinical trials exclude individuals with personal or family histories of psychotic disorders or bipolar I disorder.

### Physical risks and cardiovascular effects

Both substances have remarkably high safety ratios: psilocybin’s lethal dose is approximately 600 times the recreational dose, while LSD exceeds 1,000 times.  Standard doses produce **mild, transient elevations in heart rate and blood pressure** that rarely require intervention.   Psilocybin produces stronger blood pressure elevations; LSD produces stronger heart rate increases.  Rare case reports document cardiac events, but no systematic cardiovascular toxicity has emerged.

### HPPD (Hallucinogen Persisting Perception Disorder)

This condition involves persistent visual disturbances (visual snow, trails, after-images) after hallucinogen use.  DSM-5 suggests approximately **4.2% prevalence among psychedelic users**, though the chronic severe form (Type II) is exceptionally rare—estimated at 1 in 50,000 users. Risk factors include younger age, pre-existing anxiety, and prior psychological issues. In controlled research settings, 9.2% of healthy participants reported persisting visual symptoms, all subsiding within one week.

### Contraindications

Lithium is absolutely contraindicated—a study of 62 reports found seizures in 47% of combined use cases, with reports of heart failure and death. SSRIs and SNRIs weaken psilocybin effects significantly, with effects persisting 3-6 months after discontinuation. Special caution applies to adolescents (prefrontal cortex not fully developed until ~age 25), pregnant individuals (unstudied), and those with uncontrolled cardiovascular conditions.

——

## Direct comparison reveals practical therapeutic differences

### Duration and pharmacokinetics

|Parameter     |LSD          |Psilocybin   |
|—————|-————|-————|
|Total duration|10-11 hours  |6-7 hours    |
|Time to onset |0.4-0.6 hours|0.8 hours    |
|Time to peak  |1.6 hours    |2.3-2.5 hours|
|Half-life     |~4 hours     |~2.5 hours   |

Direct comparison research (Holze et al., 2022, *Neuropsychopharmacology*) confirmed these differences are fully explained by pharmacokinetics.  For clinical settings, psilocybin’s shorter duration significantly reduces staffing needs, facility requirements, and resource intensity. 

### Mechanistic differences

Both compounds act as 5-HT2A receptor agonists—the primary mechanism for psychedelic effects, confirmed through ketanserin blocking studies.  However, LSD shows significant binding to dopamine D1-3 receptors and most serotonin subtypes, while psilocin is more selective. Notably, psilocin inhibits the serotonin transporter similarly to MDMA, which may contribute to some unique properties.  At equivalent subjective doses, **20 mg psilocybin ≈ 100 μg LSD**.

### Current regulatory status

Both remain Schedule I controlled substances federally. Psilocybin leads in regulatory progress: three FDA Breakthrough Therapy designations versus one for LSD, active state programs in Oregon (operational January 2023) and Colorado (first regulated session June 2025), and approximately 134 registered clinical trials versus fewer for LSD. The MDMA rejection in August 2024 raised scrutiny standards, prompting companies to pivot toward drug-only models rather than psychedelic-assisted psychotherapy. 

——

## Conclusion: Two paths toward psychiatric transformation

The evidence compiled across hundreds of studies and thousands of participants establishes both LSD and psilocybin as legitimate psychiatric treatments with mechanisms now well-characterized at molecular, cellular, and network levels. The June 2025 Phase 3 success for psilocybin in treatment-resistant depression represents the clearest path toward FDA approval,  likely within the next 2-3 years pending additional trial results. LSD’s Phase 3 program for generalized anxiety disorder—notably demonstrating efficacy without psychotherapy—may offer a complementary regulatory pathway. 

The key insight emerging from comparative research is that **subjective effects are dose-dependent rather than substance-dependent**—at equivalent doses, the experiential quality is remarkably similar.  The practical difference lies in duration, making psilocybin preferable for clinical efficiency while LSD’s longer action may suit certain therapeutic contexts.

For the field, critical questions remain: optimal dosing protocols, the necessity of psychological support versus drug-only administration, long-term safety with repeated use, and effects in populations currently excluded from trials. The intersection of rigorous science with evolving state-level access programs in Oregon and Colorado will generate real-world data to complement controlled trials, potentially accelerating understanding of both benefits and risks in broader populations. 